MORGAN STANLEY PLC/CALL/BRISTOL-MYERS SQUIBB/54/0.1/20.09.24 Stock MORGAN STANLEY PLC/CALL/BRISTOL-MYERS SQUIBB/54/0.1/20.09.24
Add to a list
To use this feature you must be a member
Log inSign up

MORGAN STANLEY PLC/CALL/BRISTOL-MYERS SQUIBB/54/0.1/20.09.24 Stock

Warrant

DE000ME48AT1

Market Closed - Börse Stuttgart 12:55:01 2024-06-28 pm EDT
0.025 EUR 0.00% Intraday chart for MORGAN STANLEY PLC/CALL/BRISTOL-MYERS SQUIBB/54/0.1/20.09.24
Current month+19.05%
1 month+31.58%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Chart BRISTOL-MYERS SQUIBB COMPANY
Chart MORGAN STANLEY PLC/CALL/BRISTOL-MYERS SQUIBB/54/0.1/20.09.24

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise MT
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees MT
More news

Quotes 5-day view

Date Price Change
24-06-28 0.025 0.00%
24-06-27 0.025 -3.85%
24-06-26 0.026 +8.33%
24-06-25 0.024 0.00%
24-06-24 0.024 +14.29%

Delayed Quote Börse Stuttgart

Last update June 28, 2024 at 12:55 pm EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BRISTOL-MYERS SQUIBB COMPANY
Issuer Morgan Stanley
WKN ME48AT
ISINDE000ME48AT1
Date issued 2023-11-28
Strike 54 $
Maturity 2024-09-20 (83 Days)
Parity 10 : 1
Emission price 0.34 €
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.39 €
Lowest since issue 0.016 €
Spread 0.016 €
Spread %40.00%

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Sector
-
More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Consensus: Bristol-Myers Squibb Company

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.53 USD
Average target price
53.19 USD
Spread / Average Target
+28.09%
Consensus
  1. Stock Market
  2. Warrants
  3. Warrant